Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
- PMID:11133743
- DOI: 10.1182/blood.v97.1.63
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft
Abstract
Administration of donor T cells expressing the herpes simplex-thymidine kinase (HS-tk) with a hematopoietic stem cell (HSC) transplantation could allow, if graft-versus-host disease (GVHD) was to occur, a selective in vivo depletion of these T cells by the use of ganciclovir (GCV). The study evaluates the feasibility of such an approach. Escalating numbers of donor HS-tk-expressing CD3(+) gene-modified cells (GMCs) are infused with a T-cell-depleted bone marrow transplantation (BMT). Twelve patients with hematological malignancies received 2 x 10(5) (n = 5), 6 x 10(5) (n = 5), or 20 x 10(5) (n = 2) donor CD3(+) GMCs/kg with a BMT from a human leukocyte antigen (HLA)-identical sibling. No acute toxicity was associated with GMC administration. An early increase of circulating GMCs followed by a progressive decrease and long-lasting circulation of GMCs was documented. GCV treatment resulted in significant rapid decrease in circulating GMCs. Three patients developed acute GVHD, with a grade of at least II, while one patient developed chronic GVHD. Treatment with GCV alone was associated with a complete remission (CR) in 2 patients with acute GVHD, while the addition of glucocorticoids was necessary to achieve a CR in the last case. Long-lasting CR occurred with GCV treatment in the patient with chronic GVHD. Unfortunately, Epstein-Barr virus-lymphoproliferative disease occurred in 3 patients. Overall, the administration of low numbers of HS-tk-expressing T cells early following an HLA-identical BMT is associated with no acute toxicity, persistent circulation of the GMCs, and GCV-sensitive GVHD. Such findings open the way to the infusion of higher numbers of gene-modified donor T cells to enhance post-BMT immune competence while preserving GCV-sensitive alloreactivity.
Similar articles
- Early immune response against retrovirally transduced herpes simplex virus thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response?Mercier-Letondal P, Deschamps M, Sauce D, Certoux JM, Milpied N, Lioure B, Cahn JY, Deconinck E, Ferrand C, Tiberghien P, Robinet E.Mercier-Letondal P, et al.Hum Gene Ther. 2008 Sep;19(9):937-50. doi: 10.1089/hum.2007.156.Hum Gene Ther. 2008.PMID:18810797
- Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.Garin MI, Garrett E, Tiberghien P, Apperley JF, Chalmers D, Melo JV, Ferrand C.Garin MI, et al.Blood. 2001 Jan 1;97(1):122-9. doi: 10.1182/blood.v97.1.122.Blood. 2001.PMID:11133751
- Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux JM, Contassot E, Murphy WJ, Lyons R, Chiang Y, et al.Tiberghien P, et al.Blood. 1994 Aug 15;84(4):1333-41.Blood. 1994.PMID:8049449
- Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation.Tiberghien P.Tiberghien P.J Intern Med. 2001 Apr;249(4):369-77. doi: 10.1046/j.1365-2796.2001.00809.x.J Intern Med. 2001.PMID:11298857Review.
- [Modulation of alloreactivity using genetically modified T lymphocytes].Tiberghien P.Tiberghien P.Transfus Clin Biol. 1997;4(3):275-80. doi: 10.1016/s1246-7820(97)80052-3.Transfus Clin Biol. 1997.PMID:9264785Review.French.
Cited by
- The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions.Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, Li Z, Ni R, Li L, Su H, Liu Y.Li Y, et al.Front Pharmacol. 2022 Oct 14;13:950923. doi: 10.3389/fphar.2022.950923. eCollection 2022.Front Pharmacol. 2022.PMID:36313336Free PMC article.Review.
- Infusion of donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene for recurrent hematologic malignancies after allogeneic hematopoietic stem cell transplantation.Hashimoto H, Kitano S, Ueda R, Ito A, Tada K, Fuji S, Yamashita T, Tomura D, Nukaya I, Mineno J, Fukuda T, Mori S, Takaue Y, Heike Y.Hashimoto H, et al.Int J Hematol. 2015 Jul;102(1):101-10. doi: 10.1007/s12185-015-1801-5. Epub 2015 May 7.Int J Hematol. 2015.PMID:25948083Clinical Trial.
- CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.Peng L, Sferruzza G, Yang L, Zhou L, Chen S.Peng L, et al.Cell Mol Immunol. 2024 Oct;21(10):1089-1108. doi: 10.1038/s41423-024-01207-0. Epub 2024 Aug 12.Cell Mol Immunol. 2024.PMID:39134804Free PMC article.Review.
- Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.Tani K.Tani K.Int J Hematol. 2016 Jul;104(1):42-72. doi: 10.1007/s12185-016-2030-2. Epub 2016 Jun 11.Int J Hematol. 2016.PMID:27289360Review.
- iCaspase 9 Suicide Gene System.Zhou X, Di Stasi A, Brenner MK.Zhou X, et al.Methods Mol Biol. 2015;1317:87-105. doi: 10.1007/978-1-4939-2727-2_6.Methods Mol Biol. 2015.PMID:26072403Free PMC article.Clinical Trial.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials